What this is
- How it works
- How it works isn't classified yet
- Tested for
- Overweight , Obesity
- Main trialPhase 1
- “The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.”In the company’s words, NCT07487376 on ClinicalTrials.gov
Other drugs for Overweight , Obesity
- RetatrutideEli Lilly · Phase 3
- TradipitantVanda Pharmaceuticals · Phase 3
- LiraglutideNovo Nordisk · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- HRS-7535Hengrui · Kailera · Phase 3
- IN-B00009HK inno.N · Phase 3
Coming up1
- May 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | May 2027 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026